A note of caution on yellow fever vaccination during maraviroc treatment: A hypothesis on a potential dangerous interaction

AIDS

Volumn 23, Issue 4, 2009, Pages 542-543

  Roukens, Anna H ^a   Visser, Leo G ^a   Kroon, Frank P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC; YELLOW FEVER VACCINE;

CD4+ T LYMPHOCYTE; CHROMOSOME MUTATION; DRUG BINDING; DRUG INDUCED DISEASE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; PRIORITY JOURNAL; TICK BORNE ENCEPHALITIS FLAVIVIRUS; WEST NILE FLAVIVIRUS; YELLOW FEVER; YELLOW FEVER VACCINE ASSOCIATED VISCEROTROPIC DISEASE;

ANTI-HIV AGENTS; CYCLOHEXANES; DRUG INTERACTIONS; HUMANS; MUTATION; RECEPTORS, CCR5; TRIAZOLES; YELLOW FEVER VACCINE;

EID: 62349137331     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328323aeb4     Document Type: Letter

References (8)

1. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
2. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087-1098.
3. Glass WG, McDermott DH, Lim JK, LekhongS, Yu SF, Frank WA, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40.
4. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a metaanalysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262-265.
5. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-269.
6. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008; 198:500-507.
7. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw AD, Chen RT, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005; 23:3256-3263.
8. Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Morb Mortal Wkly Rep 2002; 51:1-10.